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Abstract
 
Arthritis in the K/BxN mouse model is provoked by pathogenic antibodies (Abs) directed
against a ubiquitously expressed protein, glucose-6-phosphate isomerase (GPI). To begin dis-
secting the repertoire of arthritogenic immunoglobulins (Igs) in the K/BxN model, and to pro-
vide a basis for comparison with RA patientswe have generated anti-GPI monoclonal Abs
(mAbs) from spontaneously activated B cells in the lymphoid organs of arthritic mice. B cell
clones with anti-GPI specificities were present at extraordinarily high frequencies in the spleen,
and less frequently in other lymphoid organs and in the synovial fluid. None of the anti-GPI
mAbs induced arthritis when injected individually into healthy recipients, but most were effec-
tive when combined in pairs or larger pools. Arthritogenic combinations depended on mAbs of
 
the IgG1 isotype, which bound to GPI with Kd in the 10
 
 
 
9
 
 M range, with no indication of co-
operative binding between complementing pairs. Pathogenicity was not associated with recog-
nition of a particular epitope, but the ability to form mAb/GPI multimers by simultaneous rec-
ognition of different epitopes was clearly required, consistent with the known role of
complement and FcRs in this model. Sequence analysis revealed structural similarities amongst
the mAbs, indicating that a particular subset of B cells may evade tolerance in K/BxN mice, and
that affinity maturation by somatic mutation likely takes place. These results confirm that GPI
itself, rather than a cross-reactive molecule, is the target of pathogenic Igs.
Key words: autoimmunity • arthritis • autoantibodies • glucose-6-phosphate isomerase • 
mouse model
 
Introduction
 
A wide spectrum of auto-Abs can be found in rheumatoid
arthritis (RA) and related arthridites, not only the rheuma-
toid factor typical of RA patients, but also a variety of other
reactivities. However, the true role of auto-Abs in the
pathogenesis of these diseases has been a matter of substan-
tial controversy (1). The best way to assign a disease-pro-
voking function to a given auto-Ab is to transfer it into a
healthy recipient and reproduce disease manifestations, as
has been done for several autoimmune diseases, including
autoimmune thrombocytopenic purpura (2) and pemphi-
gus vulgaris (3). A few experiments involving transfer of
human sera from arthritic patients into normal individuals
have been performed, but did not provoke pathology. It is
possible that too few donors or recipients were sampled,
that inappropriate experimental read-outs were used, par-
ticularly for transfers across species, or that transferred doses
were too low. Nonetheless, these data contributed to a ma-
jor shift to T cell–centric paradigms of RA pathogenesis
(e.g., reference 4). In recent years, however, studies of
multiple murine models of arthritis have demonstrated an
important role for pathogenic Igs in triggering the effector
phase of this disease (5–7). Understanding the mechanism
of action of these murine arthritogenic Igs could yield new
insights into the pathogenesis of human arthritis.
K/BxN TCR transgenic (tg) mice express a transgene-
encoded TCR reactive to a self-peptide derived from the
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ubiquitously expressed glycolytic enzyme, glucose-6-phos-
phate isomerase, presented by the MHC class II molecule
A
 
g7
 
 (7–9). These animals spontaneously develop a very ag-
gressive form of arthritis, beginning at 3 to 4 wk of age. As
in humans, the disease is chronic, progressive, and symmetri-
cal, and it exhibits all of the classical histological features: leu-
kocyte invasion, synovitis, pannus formation, cartilage, and
bone destruction. The articular manifestations are the result
of arthritogenic Abs directed against GPI, which develop at
high titers in K/BxN mice because of the preferential help
that B cells expressing GPI-specific Igs receive from GPI-reac-
tive T cells displaying the transgene-encoded TCR. Affin-
ity-purified anti-GPI IgG from these mice can transfer dis-
ease to healthy recipients in the absence of any lymphocytes.
A great paradox in the K/BxN model is the exquisite
specificity of the joint attack provoked by the auto-Abs, re-
active against a ubiquitously expressed antigen. GPI is a cy-
toplasmic enzyme, essential for basic carbohydrate metabo-
lism, and is normally sequestered in the cell cytoplasm, only
being released in the circulation in minute amounts in con-
ditions that involve cell damage or apoptosis (for refs, see
reference 9). One possible resolution to the paradox is that
the anti-GPI Abs are cross-reactive to a joint-specific anti-
gen. It was therefore important to analyze the specificity
of the anti-GPI response. We derived hybridomas from
K/BxN mice, screening for anti-GPI reactivity by an
ELISA; we report the molecular and biophysical properties
of a panel of anti-GPI mAbs, in relation to their capacity to
induce arthritis.
 
Materials and Methods
 
Mice.
 
KRN TCR tg mice have been described (8). They were
maintained on the C57Bl/6 (B) background. Crossing these K/B
animals with NOD/Lt (N) mice generated arthritic K/BxN off-
spring. Balb/c mice were 4 wk old when used as serum recipients.
 
mAbs.
 
Hybridomas producing anti-GPI mAbs were gener-
ated using standard procedures. Single-cell suspensions were pre-
pared from different organs of arthritic K/BxN mice of different
ages and, without prior culture or stimulation, were fused to the
nonsecreting myeloma cell line P3X63-AG8.653. The primary
plates were screened for Ab production by ELISA against recom-
binant GPI. Positive wells were subcloned two or three times by
limiting dilution and selection for GPI reactivity, and were ex-
panded. mAbs were purified from supernatants on protein G
Sepharose (Amersham Pharmacia Biotech), and bound IgG was
eluted in 0.1 M glycine (pH 2.8) and quickly neutralized with
1/6 volume of 1 M Tris HCl (pH 8.5). The eluted fractions were
concentrated and switched to PBS buffer by centrifugation (Cen-
tricon-30; Amicon) and then titered by ELISA for anti-GPI ac-
tivity. Heavy and light chain VDJ regions were sequenced from
amplified mRNA (see online supplemental data).
ELISAs were performed as described (9). Briefly, 96-well flat-
bottom ELISA plates (Maxisorb; Nunc) were coated with 5 
 
 
 
g/
ml of recombinant GPI as a fusion protein with glutathione
S-transferase (GST) (9) or 5 
 
 
 
g of GST in PBS at 4
 
 
 
C overnight.
They were then blocked with bovine BSA, incubated with the
supernatant, washed, and incubated with alkaline phosphatase–
coupled Abs to mouse total IgG (or, when appropriate, with iso-
type-specific anti-IgG1, -IgG2a, -IgG2b, or -IgG3 reagents
[Jackson ImmunoResearch Laboratories]).
 
Arthritis Transfer.
 
Sera from paired lots of K/BxN mice or
control BxN littermates (40 to 60 d of age) were pooled and in-
jected intraperitoneally, in 150–250 
 
 
 
l total volume (adjusted
with PBS if necessary). In most cases, recipients got two injections
at a two-day interval. Purified mAbs were also injected at a 2 d in-
terval. Arthritis was scored by clinical examination (clinical index
as described [10], caliper measurement of ankle thickness [7, 11]).
 
Surface Plasmon Resonance Analyses.
 
Surface plasmon reso-
nance (SPR) measurements were performed with a BIAcore
2000 (Biacore) as detailed in oneline supplemental data, with rab-
bit anti–mouse Fc or anti-GPI mAbs immobilized on the sensor
chip via amino groups (12). Soluble rGPI (9) was injected in the
fluid phase, and data were fitted to 1:1 Langmuir binding or to
two-state conformational change models (BIA evaluation 3.0
software). For the two-Ab assays, the capturing anti-GPI mAb1
was directly immobilized on the sensor chip at high density (3 to
10 kRU). GPI was injected for 10 min, and the mAb-GPI com-
plexes washed, leaving stable mAb1–GPI complexes. The second
mAb2 was then injected, and its binding quantitated as the molar
ratio (MR) of the reactant by the following relationship: (MR 
 
 
 
[RUmAb/ RUAg]) 
 
 
 
 [MWAg/MWmAb]) (13).
 
Online Supplemental Data Section.
 
Online supplemental
material is available at http://www.jem.org/cgi/content/full/
jem.20011941/DC1
 
Results and Discussion
 
An Extraordinarily High Frequency of GPI-reactive B Cell
Clones in K/BxN Mice.
 
As the self-reactive T cells of
K/BxN mice constantly stimulate B cells capable of inter-
nalizing GPI and presenting peptides derived from it, we
hypothesized that GPI-specific B cells would be highly
represented among the activated, Ig-secreting population
in these animals, and that they would be amenable to fu-
sion without additional immunization. To establish the op-
timum age for hybridoma production, we titered anti-GPI
Abs in the sera of a large panel of different-aged K/BxN
mice. Anti-GPI specificities were detectable at the very on-
set of disease, and increased markedly to reach a plateau at
around 60 d of age (Fig. 1). Hybridoma fusions were sub-
sequently performed with cells from different lymphoid
organs of young donors at the initiation of arthritis mani-
festations (day 29) and with older donors exhibiting well-
established disease and higher Ab titers (50–60 d).
Many GPI-reactive hybridomas resulted from these fu-
sions, the fraction of positive wells in the first screening pro-
gressing with age (Table I). This fraction reached impressive
levels (100% in two different experiments) with splenocytes
from animals older than day 50. The plating densities after fu-
sion and during HAT selection were such that an average of
2 to 4 B cell clones grew in each well. Thus, while it is not
possible to formally deduce clonal frequencies from these
data, they do suggest that a major proportion (25%, if not
more) of Ig-secreting B cells in the spleen of K/BxN mice
produce anti-GPI Abs. These numbers are consistent with
the very high anti-GPI titers in the serum. This impressive
representation probably reflects the power of T-B cell coop-
eration in such animals (7), as those B cells able to pick up the
very low concentrations of circulating GPI via high-affinity
surface receptors will preferentially receive T cell help. The 
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KRN TCR tg is unusual in this regard, as such an amplifica-
tion of matching B cells has not been observed in other au-
toreactive TCR tg animals. This property may be a peculiar-
ity of the clonotype-expressing T cells and their escape from
complete clonal deletion (8), the manner in which GPI-reac-
tive B cells are tolerized, or the biochemistry of GPI itself.
Interestingly, isotype usage also varied with age: anti-
GPI Igs of the IgG2b and IgG2a isotypes were found with
younger mice, but the proportion of IgG1 increased to be-
come the exclusive isotype with older animals (Table I), in
keeping with the dominance of IgG1 anti-GPI Abs in sera
from K/BxN mice (8).
In contrast to spleen, much more modest frequencies of
anti-GPI hybridomas resulted from fusions of lymph node or
 
bone marrow cells (Table I). Attempts were also made to fuse
lymphocytes from the synovial fluid of arthritic joints, but few
wells showed hybridoma growth, and these were not GPI-
reactive (not shown), consistent with the low abundance of B
cells in the K/BxN arthritic lesion. Thus, the spleen appears to
be the main site of production of anti-GPI Abs in this model.
 
Arthritogenic Activity of mAbs.
 
The pathogenic potential
of these mAbs was then tested. In pilot studies, small-scale
preparations of Igs were made from minimally expanded un-
cloned hybridomas; in other experiments, the hybridoma cells
were transferred directly into irradiated mice. No arthritic re-
cipients were ever observed, testing an aggregate of 40 GPI-
reactive hybridomas. In parallel, a panel of hybridomas was
selected and subcloned twice by limiting dilution. Secreted
Figure 1. Anti-GPI Abs at different ages.
Serum from K/BxN mice (filled circles) or
transgene-negative littermates (open circles)
was tested by ELISA. Titers were determined
as the serum dilution for anti-GPI reactivity
fivefold above background. Each point rep-
resents an individual mouse. Inset: results
from mice at early ages (note the different
scale for the titers). Arrows: day of arthritis
onset (day 30   3) in most K/BxN mice.
 
Table I.
 
Frequency of GPI-reactive Wells in the Initial Screens
 
Isotype among GPI-reactive (%)
Fusion Age (d) Organ No. of wells screened Percent GPI reactive
 
a
 
IgG1 IgG2b IgG2a
1 29 Spleen 175 8 nd nd nd
2 29 Spleen 137 12 70 23 6
9 35 Spleen 207 13 89 11 0
7 40 Spleen 264 42 100 0 0
6 50 Spleen 290 100 100 0 0
5 60 Spleen 128 100 100 0 0
7 40 Bone marrow 33 3 100 0 0
8 50 Bone marrow 300 7 100 0 0
8 50 Lymph node 65 20 100 0 0
 
a
 
Proportion of positive wells. Fusion efficiencies were comparable in the various experiments, with an average of 2–4 hybridoma clones in each well. 
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IgG was purified and tested for arthritogenic activity by injec-
tion into naive Balb/c recipients, using regimens and doses
that consistently gave disease with affinity-purified serum
anti-GPI IgG. Balb/c was the recipient of choice because, of
the common strains, it shows the highest susceptibility to
K/BxN serum-induced arthritis (11). Again, none of the in-
dividual mAbs could induce either clinical symptoms of arthri-
tis or histological manifestation of a joint disorder (Table II).
In contrast, pools of the mAbs did provoke arthritis. The
pool of all nine mAbs induced a severe and robust disease
(Table II), characterized by a rapid onset and joint swelling
largely equivalent to that observed with polyclonal prepara-
tions of anti-GPI IgG. The histological alterations were com-
parable with those described previously, including inflamma-
tory infiltration of the synovium and articular cavity, synovial
hyperplasia, pannus formation, and cartilage erosion (data not
shown). As is typical of K/BxN arthritis, spontaneous or in-
duced by serum transfer, there was a strong distal predomi-
nance. The pool induced the same disease manifestations in
lymphoid-deficient RAG
 
o/o
 
 mice (not shown). Robust dis-
ease could also be conferred by a subset of seven Abs, all of
the IgG1 isotype, or by smaller pools of only four, three, or
even two mAbs. Yet, as the number of Abs was reduced, the
disease became less reproducible and less aggressive (Table II).
To test which mAbs were most effective at comple-
menting each other, we injected all 36 possible pairwise
combinations into Balb/c recipients (Fig. 2 A). Only 10 of
these were able to provoke clinical symptoms of disease,
which in some cases reached the maximum score of 4 and
showed the typical histological alterations described above.
However, whereas the injection of serum Ig or larger pools
caused aggressive disease in nearly 100% of the recipients,
such a high incidence was never achieved with the mAb
pairs; rather, when arthritis could be induced, it showed
partial penetrance. With the marked exception of the two
 
IgG2b mAbs, all individual Abs within the pool partici-
pated to at least some extent in arthritogenic pairs.
All of the arthritogenic combinations involved IgG1 Abs,
confirming that anti-GPI Igs of this isotype are capable, on
their own, of inducing arthritis
 
.
 
 Mouse IgG1 has a very poor
capacity for interacting with C1q, the initiator of the classical
pathway of complement activation. Thus, Abs of this isotype
would seem, at first, to be unlikely candidates for the initiat-
ing agent in a model totally dependent on complement acti-
vation (11). However, we have recently found that it is the
alternative, not the classical, pathway that is involved in ar-
thritis induction by anti-GPI Abs (10). In the alternative
pathway, Igs enhance C3 activation by binding C3b in a co-
valent fashion, thus preventing its inactivation by factor H.
Mouse IgG1 is quite active in this regard (14). Multimerized
IgG1 is also efficient at activating Fc
 
 
 
RIII, the dominant
player in the second arm of the K/BxN effector phase (10).
Thus, the identification of IgG1 as the main and only re-
quired isotype for pathogenesis is fully consistent with what
we know so far about the effector mechanisms in K/BxN
arthritis. As IgG1 is an isotype that is tightly associated with
Th2-biased help and IL-4 activities, these two elements may
be elements of K/BxN pathogenesis. The implication is
that, if this model proves relevant to human arthritis, one
should view with great circumspection proposed therapeutic
protocols involving Th2-promoting regimens.
 
Kinetics and Affinity of the Anti-GPI mAbs.
 
To generate
clues about why some mAb pairs, but apparently not oth-
ers, could complement for arthritis induction, we measured
the binding kinetics and GPI affinity of the nine mAbs via
Biacore analysis.
First, experimental conditions were optimized to limit the
complexity of the analyzed interaction. To eliminate mass
transport as a limiting factor, we captured small quantities of
mAbs (100 RU) on anti-Fc surfaces. Before kinetic runs, each
 
Table II.
 
Anti-GPI mAbs Can Induce Arthritis when Combined, but Not Individually
 
Injection Dose Max CI Onset (d)
 
  
 
Ankle thickness (mm)
 
a
 
Individual mAbs 2 
 
  
 
1 mg 0, 0 – –
2.56
 
a
 
, 2.67
 
a
 
, 1.8, 6.121, 
2.99,6.96, 6.65, 1.24, 6.149
Pools
All nine (2 
 
  
 
222 
 
 
 
g/ea) 4, 4, 4, 3 3, 1, 2, 2 0.32, 0.73, 0.86, 0.73
All IgG1s (all but 2.56 and 2.67) (2 
 
  
 
286 
 
 
 
g/ea) 3, 3 4, 3 1.01, 0.8
1.8 
 
  
 
6.121 
 
  
 
6.149 
 
  
 
6.96 (2 
 
  
 
500 
 
 
 
g/ea) 4, 0, 2, 2, 1 3, –, 3, 3, 4 0.8, –, 1.01, 1.1, 0.9
1.8 
 
  
 
6.121 
 
  
 
6.149 
 
  
 
6.65 (2 
 
  
 
500 
 
 
 
g/ea) 3, 4 1, 3 1.11, 0.93
2.56 
 
  
 
2.67 
 
  
 
6.149 (2 
 
  
 
660 
 
 
 
g/ea) 1, 0, 0, 4, 1, 0 24, –, –, 2, 6, –
1.8 
 
  
 
6.65 
 
  
 
6.149 (2 
 
  
 
660 
 
 
 
g/ea) 4, 4, 2.5, 4, 4 1, 1, 1, 2, 2 1.19, 0.96, 0.51, 0.99, 0.99
6.121 
 
  
 
6.65 
 
  
 
6.149 (2 
 
  
 
660 
 
 
 
g/ea) 3, 4, 2.5 1, 2, 2 0.81, 0.98, 0.58
6.65 
 
  
 
6.149 (2 
 
  
 
1 mg/ea) 2, 0, 1, 0 3, –, 1, –
Abs purified by protein-G chromatography were injected into 4-wk-old Balb/c recipients either individually or as pools. Arthritis was scored as
clinical index and by measurement of ankle thickening (represented as the difference between thickness at day 7 and day 0).
 
a
 
IgG2b (all others IgG1). 
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mAb surface was tested by injecting the lowest concentration
of GPI, at variable flow rates. Flow rates had no effect on
binding rates, indicating that mass transport limitations were
not an issue (15). The nine mAbs were analyzed by measuring
the binding of soluble GPI injected in the fluid phase (Table
III; online supplemental data). In general, all mAbs had a high
affinity for GPI, with a K
 
d
 
 of 5 
 
 
 
 10
 
 
 
8
 
 M or better. Simple
1:1 Langmuir binding models fit readily the curves of two sets
of mAbs: one group (“low k
 
off
 
” mAbs), which includes mAbs
 
2.56, 6.149, 1.8, and 6.96, formed complexes with GPI with
a half-life of 
 
 
 
1/2 h. A second group (“very low k
 
off
 
” mAbs),
consisting of 6.65 and 1.24, formed complexes more stable by
an order of magnitude. A third set included mAbs 2.67,
6.121, and 2.99, whose interaction with GPI was more com-
plex, a two-state reaction involving a conformational change
that stabilizes the complex (A 
 
  
 
B 
 
↔
 
 AB 
 
↔ 
 
AB
 
*
 
) giving the
best fit with the experimental data.
In general, arthritogenic pairs tended to involve the mAbs
with the slowest off-rates (6.65, 1.24), but this was not an ab-
solute. Complementation did not necessarily require combi-
nation of mAbs with different affinities or dissociation rates.
As a minimum of two mAbs was needed to provoke dis-
ease, an immediate question was whether simultaneous
binding of these arthritogenic pairs to GPI was required to
initiate the events culminating in joint inflammation, or
whether complementing but uncoordinated binding of dif-
ferent molecules was involved. The former would be nec-
essary should complementation function by inducing cross-
linking of GPI into multivalent complexes. Therefore, dual
interactions were examined. Saturating amounts of capture
mAb (mAb1) were first immobilized, and stable complexes
were formed by injecting GPI. A second mAb (mAb2) was
then injected and its interaction with the mAb1–GPI com-
plex evaluated; the signal increment due to the binding of
mAb2 was expressed as molar ratio (MR) values (Fig. 2 B).
Some mAb pairs were mutually incompatible (MR of 0;
for example 2.67/6.121, or 2.99/6.96), most likely due to
overlapping epitopes. On the other hand, many of the mAb
pairs were characterized by a significant MR, indicating that
they could bind simultaneously to GPI. Most of these inter-
actions were symmetrical, as would have been predicted, al-
though this was not always the case. In some instances, it
was important which Ab bound to GPI first: for example,
1.24 could bind to the 2.67–GPI complex, but the opposite
did not happen. The epitope map resolved the mAbs into
four groups. According to the 
 
M
 
r
 
 criterion, mAbs 2.67, 1.8,
and 6.121 could be grouped together, as they bound to the
same cluster of epitopes, showing a similar, although slightly
different, pattern of recognition. The second group corre-
sponded to mAbs 2.99 and 6.96, while mAbs 6.65 and 1.24
were distinct. From competitive ELISA results (not shown),
6.149 would belong to the same group as 1.24. Comparison
of these cobinding patterns with the pathogenicity of indi-
vidual pairs (Fig. 2 B) clearly showed that corecognition of
the same GPI molecule was required for arthritogenesis:
none of the cross-blocking pairs induced disease.
As illustrated above, the more individual Abs injected, the
more robust the disease. The data rule out several potential
explanations for this phenomenon. First, it does not reflect
a need for effector functions mediated by Abs of different
isotypes, as IgG1 mAbs alone sufficed. Nor does it reflect
epitope unmasking and cooperative binding — rather, if
anything, the opposite. On the other hand, these patho-
genic mAbs had to bind GPI simultaneously, and the im-
provement in disease induction with increasing mAb num-
ber implies that large multimeric complexes must be
formed. This notion of large Ab/Ag complexes is consistent
Figure 2. Complementing pairs of anti-GPI mAbs. (A) Pairs of mAbs
were tested by injection into healthy mice. Black squares indicate patho-
genicity (clinical score  1, incidence  20%), white squares no clinical or
histological lesions (at least two mice tested for each pair). Illustrative day
of onset and maximum arthritis scores are shown below. (B) Anti-GPI
mAbs were tested as pairwise combinations in Biacore experiments,
where Ab1 was first bound to the chip, GPI was added, and the binding
of the second Ab tested for reactivity to the preformed Ab1-GPI com-
plex. Data are expressed as molar ratio, representing the relative increase
in signal generated by binding of the second antibody (0, no binding; 1,
theoretical maximum binding). Black squares represent an absence of
binding over background, gray squares detectable binding of Ab2. 
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with recent observations demonstrating the requirement for
two major inflammatory effector arms in K/BxN arthritis:
complement activation and FcR signaling (10). Complement
activation is enhanced by Ig deposition and immune com-
plexes, and the cross-linking of multiple FcRs by immobi-
lized Igs arrays is most effective at initiating a functional re-
sponse (16). As discussed elsewhere (17), multimerization
may correspond either to deposition of preformed complexes
that can be found circulating in the serum of K/BxN mice,
or to multimeric stabilization of arrayed GPI on joint surfaces.
Whichever the explanation (or both?), the data presented
here indicate that multimerization of GPI/anti-GPI com-
plexes is an essential component of K/BxN pathology.
Dual-binding assays showed that mAb pairs that could not
bind simultaneously were ineffective at inducing arthritis.
However, there was no explanation for other pairs that were
capable of simultaneous binding yet were ineffective at in-
ducing arthritis. These pairs might induce an infrequent dis-
ease that would not have been detected with the limited
groups involved. They might also fall just below the threshold
for productive activation — none of the mAb pairs was very
efficient in any case. Or, more interestingly, the relative mo-
lecular angles adopted by these mAb1-GPI-mAb2 complexes
might preclude assembly into larger lattices. These negative
results must be treated with a certain degree of caution, how-
ever, as these combinations were not tested extensively.
The requirement for more than one mAb for disease in-
duction has also been described in another mouse model of
arthritis: a minimum combination of three anti-collagen II
mAbs was needed to provoke collagen-induced arthritis
(CIA; reference 6), suggesting that similar effector mecha-
nisms might be involved in the two models. This is consis-
tent with the fact that genetic factors that influence arthritis
in the K/BxN and CIA models appear quite similar (18,
19). However, there are some interesting differences in the
effects of mAbs in the two cases. First, there is obviously far
more collagen-II than GPI in the joint, and so one might
have expected anti-collagen to be more effective than anti-
GPI at eliciting inflammation. But the opposite was true, as
the doses of Ig required for the latter were markedly lower
than the 10 mg of anti-collagen mAbs routinely used. Sec-
ond, the dominant and most efficient isotype of anti-GPI
mAbs was IgG1, while the best results were obtained with
a cocktail of IgG2a and IgG2b anti-collagen mAbs (6), in
keeping with earlier observations that IgG2 subclasses cor-
related with CIA pathology (20).
 
Ig Gene Usage.
 
V
 
H
 
 and V
 
L
 
 nucleotide sequences were
determined for the nine anti-GPI mAbs by PCR amplifica-
tion with degenerate primer, followed by sequencing of the
PCR products (results presented in the online supplemental
data). As the mAbs were derived from the spleens of several
different mice, most should have been clonally indepen-
dent. The sequences confirmed this, none of the heavy or
light chain sequences of the nine mAbs being identical to
another. On the other hand, there are distinct similarities
between the heavy chains: six are encoded by genes derived
from the V
 
H
 
1 family (aka J558), particularly intriguing as
the V
 
H
 
s used in 1.8, 6.121, 2.56, and 2.67 all stem from
subgroup 20; in addition, 6.149 and 6.96 are both encoded
by the V
 
H
 
14 gene (aka SM7). V
 
 
 
 gene usage shows no such
restrictions, since 5 different V
 
 
 
 gene families encode the
light chains of 8 of the anti-GPI mAbs in the pool.
The V
 
H
 
 and V
 
L
 
 sequences were compared with the germ-
line genes. A large number of mutations is observed (from 3
to 36, median 18), the majority leading to amino acid re-
placements (online supplemental data). It is not possible to
 
Table III.
 
Kinetics Constants of Anti-GPI mAbs–GPI Interactions
 
Low k-off mAbs Very low k-off mAbs Biphasic dissociation mAbs
Kinetics
parameters 2.56 6.149 1.8
 
a
 
6.96 1.24
 
a
 
6.65 2.99 6.121 2.67
 
a
 
k
 
off
 
1   10 4 (s 1) 3.3   0.01 6   0.1 3.6   1.4 4.7   0.01 0.2   0.1 0.5   0.01 65   0.7 40   0.3 100   4
2   10 4 (s 1)– – –– – – 5     0.03 2   0.03 2.9   0.4
t1/2 1 min 35 19 32 24 640 240 2 3 1
2 min – – – – – 23 60 40
kon 1   10 4 (M 1s 1) 5.0   0.01 11.6   0.06 42   0.9 78   0.1 14.6   0.2 9.2   0.01 54   0.2 78   0.2 180   10
2   10 4 (M 1s 1) – – – – – – 37   0.2 28   0.2 56   18
kd   10 9 (M)b 6.6 5 0.8   0.3 0.6 0.12   0.07 0.5 1.6 0.37 1.8   0.03
Pathogenicityc 03 2 2 2 622 0
Kinetic data were obtained by capturing mAbs by a first anti-IgGFc (RAM) immobilized on the dextran and using GPI as soluble analyte. Association
(kon) and dissociation (koff) rate constants were obtained by numerical integration combined with global fitting using five different GPI concentrations
(9.5 nM to 152 nM). Data were fitted to a simple 1:1 bimolecular interaction model or a two state reaction model for mAbs 2.67, 6.121, and 2.99.
The quality of the fits was assessed by the random distribution of the residuals and  2 values usually below 3.0.
aFor mAbs 2.67, 1.8, and 1.24, the kinetic constants are the mean   SD of data obtained on two different sensor chips.
bThe Kd are obtained from the ratio koff/kon and for mAbs 2.67, 6.121, and 2.99 from (koff1   koff2)/kon1   kon2).
cNumber of pathogenic pairwise combinations in which the antibody participates.1077 Maccioni et al. Brief Definitive Report
conclude with certainty that any single mutation arose from
somatic mutation, because the germline sequences could
have arisen from either the B6 or NOD Ig loci of the donor
K/BxN mice. On the other hand, that none of the se-
quences is identical or even closely related to any of the da-
tabase germline sequences is certainly indicative of a high
overall degree of somatic mutation. Perhaps the clearest ex-
ample entails mAbs 6.149 and 6.96: they originated from the
same mouse, and their heavy chain genes are clearly related,
as the CDR3 joining regions are identical; yet, they show
four nucleotide differences. This finding suggests a common
IgH rearrangement event and later divergence by somatic
mutation. Interestingly, sequences of anti-GPI Fabs from
human RA patients also indicated somatic mutation (21).
Conclusion. These findings finalize the identification of
GPI as the true target of the arthritogenic Igs in K/BxN
mice. First, the fact that arthritis could be induced by the in-
jection of pooled mAbs grown in vitro rules out the possi-
bility that any serum-derived contaminant, cofractionated
during the affinity purification of anti-GPI IgG (9), causes
the joint lesions. Second, earlier results did not definitively
eliminate the possibility that the anti-GPI Igs cross-reacted
with another, joint-specific, molecule, although no such
molecule could be detected (9). However, the fact that
seven different anti-GPI mAbs reactive against at least four
distinct epitopes could participate in arthritis induction ren-
ders such an explanation highly unlikely — it is difficult to
conceive of how there could be cross-reactivity between this
entire quartet and elements of another molecular species. In-
stead, multimeric crosslinking by high-affiny antibodies
seems at the root of K/BxN arthritis.
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